Condition
Ovarian Cancer Metastatic Recurrent clinical trials and research
Research outlook What's coming for Ovarian cancer: the next 6 months to 5 yearsAs of November 12, 2026, Find a Trial lists 4 Ovarian Cancer Metastatic Recurrent clinical trials that are recruiting, at sites in 4 countries (most in Israel (1), China (1), United States (1)). By phase: Phase 2 (3), Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 4Countries
Newest Ovarian Cancer Metastatic Recurrent clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| HWK-007, a PTK7-targeted antibody‑drug conjugate for advanced PTK7-positive ovarian, endometrial, and certain non‑squamous lung cancers | Phase 1 | Little Rock, Arkansas and 11 other locations | Recruiting | Mar 3, 2026 |
| Trastuzumab deruxtecan versus standard treatment for ovarian cancer that returned after PARP inhibitor therapy | Phase 2 | Seoul, Seoul | Recruiting | Jan 14, 2026 |
| Disitamab vedotin plus carboplatin and bevacizumab as first-line and maintenance treatment for HER2-expressing, HRD-negative high-risk ovarian cancer | Phase 2 | Nanjing, Jiangsu and 1 other locations | Recruiting | Dec 31, 2025 |
| Blocking stress and inflammation around surgery to slow ovarian cancer spread | Phase 2 | Ramat Gan and 1 other locations | Recruiting | Feb 21, 2025 |
All recruiting trials (4)
-
HWK-007, a PTK7-targeted antibody‑drug conjugate for advanced PTK7-positive ovarian, endometrial, and certain non‑squamous lung cancers
This study will try HWK-007, a PTK7-targeted antibody‑drug conjugate given every three weeks, to see if it can shrink or control advanced PTK7-positive ovarian, endometrial, or non-squamous EGFR wild-type lung cancers.
-
Trastuzumab deruxtecan versus standard treatment for ovarian cancer that returned after PARP inhibitor therapy
This study will test whether trastuzumab deruxtecan helps people with HER2-expressing recurrent ovarian, fallopian tube, or peritoneal cancer that progressed on prior PARP inhibitor therapy compared with standard chemotherapy or bevacizumab.
-
Disitamab vedotin plus carboplatin and bevacizumab as first-line and maintenance treatment for HER2-expressing, HRD-negative high-risk ovarian cancer
This study tests whether adding disitamab vedotin to carboplatin and bevacizumab helps people with HER2-expressing, HRD-negative high-risk ovarian cancer as first-line and maintenance treatment.
-
Blocking stress and inflammation around surgery to slow ovarian cancer spread
This trial will try giving propranolol and etodolac around the time of debulking surgery to lower recurrence and boost immune responses in women with suspected high-grade ovarian cancer.
Related topics
Quick answers
How many Ovarian Cancer Metastatic Recurrent clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 4 countries. The most sites are in Israel (1 trial), China (1 trial), United States (1 trial), South Korea (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 3, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.